Alzheimer’s disease research has taken center stage in the world of drug discovery and clinical development. The convergence of causal AI, supercomputing power, and multi-omic human data is allowing us to begin to unravel the molecular circuity of this debilitating disease in order to discover the next generation of breakthrough drugs and predictive biomarkers.
In this webinar, featuring Dr. Rudolf Tanzi, pioneer and co-discoverer of the first Alzheimer’s gene related to the β-Amyloid, John Dwyer, President of Global Alzheimer’s Platform Foundation (GAP), and Colin Hill, CEO and co-founder of Aitia, we delved into a pivotal phase in Alzheimer’s disease research. This transformative era is driven by cutting-edge technologies and innovative approaches. The convergence of causal AI, supercomputing power, and multi-omic human data holds the promise of transforming our understanding of this debilitating disease and fueling the discoveries of novel biomarkers and breakthrough drugs
If you’d like to revisit the valuable insights shared during the webinar, we have made the on-demand video available for your convenience here.